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SUMMARY
American tegumentary leishmaniasis is a vector-
borne parasitic disease caused by Leishmania proto-
zoans. Innate immune cells undergo long-term func-
tional reprogramming in response to infection or
Bacillus Calmette-Gue´rin (BCG) vaccination via a
process called trained immunity, conferring non-
specific protection from secondary infections. Here,
we demonstrate that monocytes trained with the
fungal cell wall component b-glucan confer
enhanced protection against infections caused by
Leishmania braziliensis through the enhanced pro-
duction of proinflammatory cytokines. Mechanisti-
cally, this augmented immunological response is
dependent on increased expression of interleukin
32 (IL-32). Studies performed using a humanized
IL-32 transgenic mouse highlight the clinical implica-
tions of these findings in vivo. This study represents a
definitive characterization of the role of IL-32g in the
trained phenotype induced by b-glucan or BCG, the
results of which improve our understanding of the
molecular mechanisms governing trained immunity
and Leishmania infection control.
INTRODUCTION
Leishmaniases are vector-borne tropical diseases caused by
protozoa of the Leishmania genus, characterized by a wide clin-
ical spectrum and symptoms ranging from self-healing cuta-
neous lesions to lethal visceral disease. Leishmaniases are
among of the most neglected infectious diseases with ende-
micity in 88 countries and affecting 12 million people worldwide.
The annual incidence is around 2 million cases, including both
visceral and cutaneous diseases (Alvar et al., 2012). In the Amer-
icas, L. (Viannia) braziliensis is the predominant species causing
American tegumentary leishmaniasis (ATL), characterized by
localized cutaneous leishmaniasis (LCL), disseminated cuta-
neous leishmaniasis (DL), and mucosal leishmaniasis (ML)
(Goto and Lauletta Lindoso, 2012). In the absence of efficient
strategies to prevent infections with Leishmania parasites and
to control the transmission of the parasites by vector insects,
the treatment of leishmaniasis relies on drug therapy. Pentava-
lent antimony has been the first line of treatment for decades.
This drug is expensive for low and middle-income countries
and requires several injections that are toxic and painful. Further-
more, there is emergence of parasite resistance to antimonial
drugs, and the rate of treatment failure affects more than 47%
of the cases. In some endemic areas, where the efficacy of
pentavalent antimonial is very low, it is replaced by other more
effective drugs such as amphotericin B and miltefosine (Barroso
et al., 2007; Khamesipour, 2014; Machado et al., 2010).
Leishmania is an intracellular parasite that can be taken up by
phagocytic cells, including neutrophils, monocytes, macro-
phages, and resident dendritic cells. In macrophages, there is
the best evidence for parasite replication and long term-survival
(Beattie and Kaye, 2011). Therefore, targeting macrophages to
enhance or modulate their antimicrobial function may facilitate
the development of novel therapeutic strategies. Among the
effector mechanisms used by macrophages to control Leish-
mania replication are reactive oxygen species (ROS) and reac-
tive nitrogen intermediates (RNI). Activation of macrophages is
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dependent on interferon gamma (IFNg) and tumor necrosis fac-
tor (TNF-a) (Bottrel et al., 2001; Ibraim et al., 2013; Liese et al.,
2008). Additionally, studies have shown that macrophage inter-
leukin (IL)-1b signaling is important for controlling parasite repli-
cation and influences the clinical course of Leishmaniasis (Lima-
Junior et al., 2013; Novais et al., 2017).
Recently, our group identified interleukin 32 (IL-32), an intra-
cellular cytokine produced in different isoforms by immune and
non-immune cells, as a pivotal mediator in controlling infections
caused by NewWorld Leishmania spp. (Dos Santos et al., 2018).
IL-32g is expressed in lesions of patients infected with L. (V.) bra-
ziliensis or L. (L.) amazonensis (Galdino et al., 2014; Gomes et al.,
2017). In addition, infection of human macrophages with Leish-
mania induces intracellular IL-32g expression. Once produced,
IL-32g is associated with the production of TNF-a, IL-8, nitric ox-
ide (NO), and antimicrobial peptides such as cathelicidin and
b-defensin 2 (Dos Santos et al., 2017b). Moreover, Leishmania
infection of human IL-32g transgenic (IL-32gTG) mice resulted
in improved control of lesions caused by L. braziliensis in associ-
ation with an increase of IFNg, TNF-a, and IL-10 production
(Gomes et al., 2017).
Clinical improvement in the treatment of ATL with Bacillus
Calmette-Gue´rin (BCG) vaccination has been reported previ-
ously (Convit et al., 2004). In addition, we recently confirmed
that BCG vaccination in combination with conventional treat-
ment can increase circulating natural killer (NK) cells and proin-
flammatory monocytes, contributing to clinical remission of
several lesions in a patient with diffuse cutaneous leishmaniasis
(DCL) caused by L. (L.) amazonensis (Pereira et al., 2009). Simi-
larly, Obaid et al. (1989) observed that b-glucan (a cell wall
component ofCandida albicans) as adjuvant together with Leish-
mania antigens lead to protection against L. (L.) donovani in
hamsters.
In monocytes and macrophages, BCG and b-glucan induce
non-specific protection to secondary infections by long-term
functional reprogramming via a process called trained immunity,
which is dependent on metabolic and epigenetic changes, such
as lysine methyl modifications (H3 histones monomethylated
[H3K4me1] or trimethylated [H3K4me3] at lysine 4) (Arts et al.,
2016; Netea et al., 2016; Quintin et al., 2012). We therefore hy-
pothesized that exposure of monocytes to b-glucan may induce
non-specific protection against intracellular infection caused by
Leishmania spp., which could offer novel immunotherapeutic
strategies to patients with leishmaniasis. In both human primary
cells and a murine model of trained immunity, we assessed the
effects of b-glucan or BCG training in monocytes and macro-
phages using various biochemical and molecular approaches.
In addition, we investigated the role of IL-32g and IL-1 signaling
for b-glucan-induced trained immunity.
RESULTS
b-Glucan-Induced Trained Immunity Controls
L. braziliensis Infection in Primary HumanMacrophages
Because trained immunity has been reported to protect
against non-specific infections, we investigated whether
training induced by b-glucan could control infection caused by
L. braziliensis. Human primary monocytes incubated with
b-glucan for 24 h were washed and incubated in normal culture
conditions for an additional 5 days and infected at day 6with pro-
mastigote forms of L. braziliensis. Production of TNF-a, IL-6, and
IL-10 was evaluated after 2 h, 4 h, and 24 h of infection (Fig-
ure 1A). Training of monocytes with b-glucan induced higher
TNF-a and IL-6 production after stimulation with LPS, compared
to control cells (Figures S1A andS1B). L. braziliensis infection did
not induce these cytokines in naive macrophages, whereas a
significant increase in IL-6 and IL-10 production was observed
after 2 h and 4 h of infection in b-glucan-trained macrophages
(Figures 1B–1D). In parallel, a greater percentage of macro-
phages had ingested the parasite after training with b-glucan
at these time points (Figure 1E). Remarkably, after 24 h of infec-
tion, the percentage of infected macrophages strongly
decreased in b-glucan-treated macrophages (Figure 1E). Similar
results were observed with regard to the number of parasites per
infected cell and infection index (Figures 1F and 1G). Interest-
ingly, the number of parasites per infected cell was significantly
decreased as early as 4 h after infection, indicating rapid killing of
the parasites in b-glucan-trained cells (Figure 1F). Accordingly,
b-glucan-trained macrophages contained 3-fold less live para-
sites compared to control macrophages (Figure S1C). Macro-
phages death wasmonitored bymeasuring the release of lactate
dehydrogenase (LDH). LDH concentrations remained stable in
both b-glucan-trained and control macrophages after infection
(Figure S1D).
To investigate potential mechanisms underlying these initial
observations, we evaluated whether known microbicidal mole-
cules such as ROS, NO, cathelicidin, and b-defesin could explain
the better parasite control in b-glucan-trained primary macro-
phages. No differences in ROS or NO production were observed
when comparing trained or non-trained macrophages (Figures
S2A and S2B). In contrast, cathelicidin and b-defensin 2 mRNA
expression were significantly increased in b-glucan-trained
macrophages (Figures S2C and S2D).
b-Glucan-Induced Epigenetic Modifications Results in
Upregulation of IL-32 Expression in Human
Macrophages
We previously described a role for IL-32-dependent cathelicidin
and b-defensin 2 expression in host defense against Leishmania
spp. (Dos Santos et al., 2017b), thus prompting us to explore
if IL-32 was involved in b-glucan induced protection against
L. braziliensis infection in human macrophages. In accordance
with our hypothesis, IL-32g mRNA expression as well as intra-
cellular IL-32 protein levels were significantly increased in
b-glucan-trainedmacrophages (Figures 2A and 2B). Furthermore,
when b-glucan-trained cells were infected with L. braziliensis, the
intracellular IL-32 protein levels were increased compared to con-
trol cells (Figure 2C). These results indicated that IL-32 is upregu-
lated on a transcriptional level. Indeed, intracellular IL-32
expression was previously shown to be influenced by genetic
variation in the IL-32 promoter region (https://genenetwork.nl/
bloodeqtlbrowser; Westra et al., 2013). Using the 200FG
cohort (Li et al., 2016) of healthy volunteers,we examinedwhether
the IL32 promoter single nucleotide polymorphism (SNP)
rs4786370 could interfere with b-glucan-induced trained immu-
nity. The presence of CC genotype was associated with greater
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production of TNF-a and IL-6 comparedwith the CT and TT geno-
types (Figures 2D and 2E). Additionally, in individuals carrying the
CC genotype, a tendency to higher production of lactate was
observed compared with the TT genotype (Figure 2F).
To investigate whether the IL32 rs4786370 SNP could influ-
ence the production of intracellular IL-32 and infection index dur-
ing the training with b-glucan, we stratified the healthy volunteers
based on their genotype. The tendency of higher production of
IL-32 was observed in individuals carrying the CC genotype
compared with those carrying the TT genotype in b-glucan-
trained macrophages after the infection with L. braziliensis (Fig-
ure 2G). In parallel, the infection index pointed toward a
decreased infection rate in the individuals carrying the CC geno-
type compared with the TT genotype (Figure 2H). Interestingly, a
negative correlation between the levels of intracellular IL-32 and
the infection index in the individuals carrying the CC genotype
was observed (Figure 2I). These results suggested that trained
immunity phenotype induced by b-glucan is mediated by IL-32.
We next examined the chromatin landscape surrounding IL-32
expression in cells trained with b-glucan. Levels of H3 histones
trimethylated at lysine 4 (H3K4me3), a marker generally associ-
ated with transcriptional activation, were unexpectedly depleted
from the IL-32 promoter region in trained cells (Figure 2J).
Furthermore, transcriptionally repressive lysine 9 trimethylation
of H3 histones (H3K9me3) was not significantly altered by
b-glucan training (Figure 2K). A recent study identified a distal
regulatory element that is crucial for IL-32 transcriptional regula-
tion in CD4+ T cells (Palstra et al., 2018). Activation of such ele-
ments can be epigenetically distinguished by enrichment for
H3 histones monomethylated at lysine 4 (H3K4m1) (Catarino
and Stark, 2018). Paralleling the transcriptional upregulation of
IL-32, we observed significant enrichment of H3K4m1 at the
distal enhancer region (Figure 2L).
Human Monocyte Training with b-Glucan Is Dependent
on IL-32g Expression and IL-1 Signaling
Trained immunity induced by b-glucan is reported to be depen-
dent on bioactive IL-1b production inmice (Christ et al., 2018;Mi-
troulis et al., 2018). Moreover, IL-1b induces IL-32 production
(Kim et al., 2005). To further investigate whether IL-1b and IL-32
Figure 1. Trained Immunity with b-Glucan Is Important for Controlling L. braziliensis Infection in Human Macrophages
Monocytes were trained with RPMI or b-glucan for 24 h.
(A) On day 6 after b-glucan exposure, macrophages were infected with stationary-phase L. braziliensis promastigotes for 2 h, washed, and incubated for a total of
24 h infection.
(B–D) Production of TNF-a (B), IL-6 (C), and IL-10 (D) was measured in supernatants by ELISA.
(E) Percentage of infected macrophages after 2 h, 4 h, and 24 h of infection.
(F) Number of parasites per infected cell after 2 h, 4 h, and 24 h of infection.
(G) Infection index after 2 h, 4 h, and 24 h of infection. The data shown are the mean ± SEM. Results are compiled from at least two experiments. n = 6. *p < 0.05
(RPMI versus b-glucan; by Wilcoxon test).
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Figure 2. IL-32g Is Upregulated in b-Glucan-Trained Macrophages and Is Relevant for Training
Monocytes were untrained or trained with b-glucan for 24 h.
(A and B) On day 6 after b-glucan exposure, IL-32g mRNA expression (A) and intracellular IL-32 protein (B) were measured.
(C) After b-glucan exposure, macrophages were infected with stationary-phase L. braziliensis promastigotes and intracellular IL-32 protein was measured.
(D–F) Genetic variations in IL-32 were assessed in DNA samples from 83 healthy volunteers from the 200FG cohort. On day 6, after LPS restimulation, TNF-a (D),
IL-6 (E), and lactate (F) production in b-glucan-trained macrophages was assessed in the 3 genotypes for IL-32 rs4786370 SNP. The data shown are fold
increased normalized to RPMI. Mean ± SEM; *p < 0.05 (Mann-Whitney U test).
(legend continued on next page)
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was associated with the training induced by b-glucan in primary
human cells, the production of IL-1bwere assessed in the individ-
uals carrying the different genotypes of the IL32 rs4786370 SNP.
The results showed a higher production of both secreted IL-1b
and intracellular IL-1b by individuals carrying the CC genotype
compared with the TT genotype during the first 24 h of exposure
with b-glucan (Figures 3A and 3B). The treatment of primary
monocytes with human IL-1b resulted in a significant increase
in IL-32g mRNA expression as well as intracellular IL-32 protein
levels (Figures 3C and 3D). Further, we examined the effect of ge-
netic variations in IL-1/IL-1R genes on b-glucan-induced trained
immunity. Cytokine production was significantly decreased
when there were polymorphisms located in the promoter region
of the IL-1b-encoding gene (IL-1b; rs16944) (Figures 3E and 3F)
or a missense SNP in the IL-1a gene (IL-1a, rs17561) (Figures
3G and 3H), respectively. Similarly, an intronic SNP on IL1RAP
(interleukin 1 receptor accessory protein; rs34590034) gene
also influenced the training capacity of monocytes by decreasing
the production of TNF-a by individuals carrying the TT genotype
compared to AA and AT genotypes (Figure 3I).
The effects of impaired IL-1 signaling could be ascribed to a
decrease in IL-32 production. In fact, when monocytes were
trained with b-glucan in the presence of interleukin-1 receptor
antagonist (IL-1Ra), we observed lower levels of IL-32g mRNA
than monocytes trained in the absence of IL-1Ra (Figure 3J).
Additionally, when these macrophages were infected with
L. braziliensis, we observed a significant higher infection index
than monocytes trained in the absence of IL-1Ra (Figure 3K).
The importance of IL-1b for b-glucan-induced training was
confirmed by a reduction in TNF-a and IL-6 production when
cells were trained in the presence of IL-1Ra and challenged after
6 days of culture with LPS (Figures S3A and S3B). Thus, we
showed that b-glucan-induced trained immunity is regulated
by the expression of IL-32 and IL-1 signaling, which is important
for the control of L. braziliensis infection.
b-Glucan-Induced Trained Immunity in Human IL-32g
Transgenic Mice Improves Resistance to Leishmania
braziliensis
Because IL-32 is not expressed in rodents to further confirm that
IL-32g is important for b-glucan training and control of
L. braziliensis infection, we performed experiments with human
IL-32g transgenic mice (IL-32gTG) (Choi et al., 2010). Recently,
it was reported that b-glucan-induced trained immunity in
C57BL/6 mice induced proliferation of bone marrow progenitors
of myeloid lineage, which was associated with increased pro-
duction of innate immune mediators such as IL-1b, and with ad-
aptations in cell metabolism (Mitroulis et al., 2018). Next, we
investigated whether b-glucan also induces changes in bone
marrow cells (BM) of IL-32gTG mice. Human IL-32gTG mice
received intra-peritoneal b-glucan injections, and after 7 days,
bone marrow cells were analyzed. An increased cellularity was
observed in the b-glucan-injected group compared to the PBS
control animals (Figure 4A). Furthermore, b-glucan-treated
mice displayed higher expression of mki67 and csf2rb mRNA,
which are genes related to cell-cycle regulation and a myeloid
lineage marker, respectively (Figures 4B and 4C). Of note, rag2
gene expression that is a lymphoid cell marker was downregu-
lated in b-glucan-injected group compared to the PBS control
animals (Figure 4D). We next analyzed IL-32 expression after
24 h of ex vivo stimulation with LPS or L. braziliensis lysates.
Levels of IL-32g and IL-1b mRNA were significantly higher in
BM cells from the b-glucan-injected mice compared with cells
from the PBS group after stimulation with either LPS or lysates
of L. braziliensis (Figures 4E and 4F). Besides cytokines, expres-
sion of genes encoding key regulatory enzymes of the glycolytic
pathway was evaluated. We observed significantly increased
expression of hif-1a, pfkp3, and hk3 mRNA expression in BM
cells from b-glucan-injected mice in comparison with cells
from PBS-injected IL-32gTG mice (Figures 4G–4I).
These results indicated that IL-32gTG mice can be trained by
b-glucan, leading to metabolic alterations and an improved im-
mune response to L. braziliensis antigens. Thus, we further
explored whether b-glucan could induce protection against
L. braziliensis infection in vivo in IL-32gTG mice. To this end,
either wild-type (WT) C57BL/6 or IL-32gTG mice were injected
with b-glucan or PBS and infected 7 days later with stationary-
phase promastigotes of L. braziliensis (Figure 5A). b-glucan-
trained IL-32gTG mice showed a significant increase in lesion
size after 3 weeks of infection compared with the PBS control
group. Remarkably, after week 5 of infection, a significant
decrease in lesion size was observed in b-glucan-trained mice.
Nevertheless, no significant differences in lesion size were
observed in b-glucan-trained WT mice compared with the PBS
control group (Figure 5B). At the later stages of the infection, a
significant decrease in parasite load was observed in
b-glucan-trained IL-32gTG mice compared with the PBS group.
Consistent with the lesion size, no differences in parasite load
were observed in b-glucan-trainedWTmice (8weeks, Figure 5C).
Furthermore, no significant differences in TNF-a and IL-32 levels
were observed at this time point (Figures 5D and 5E).
The increased size of the lesion on the third week of infection
observed in the b-glucan-trained mice could be ascribed to a
marked increase in the inflammatory infiltrate (Figures 6B–6D).
After 8 weeks of infection, b-glucan-trained IL-32gTG mice
showed a significant reduction of inflammation when compared
with the PBS group (Figures 6E–6G). Contrary to the IL-32gTG
mice, when b-glucan-trained WT mice were compared with the
PBS group, no significant difference in the inflammatory infiltrate
was observed (Figures 6H–6J).
(G and H) After training with b-glucan, macrophages from individuals carrying the CC and TT genotypes of IL32 rs4786370 SNP were infected with stationary-
phase L. braziliensis promastigotes. Intracellular IL-32 protein (G) was measured and the infection index (H) was determined. The data shown are the mean ±
SEM; n = 5 CC and n = 4 TT.
(I) Correlation of IL-32 with infection index in individuals carrying the CC genotype of IL32 rs4786370 SNP.
(J–L) Chromatin was fixated on day 6 and chromatin immunoprecipitation (ChIP)-qPCR was performed. H3K4me3 (J) and H3K9me3 (K) were determined at the
promoter of IL-32 gene (P1 and P2). H3K4me1 (L) was determined at the distal enhancer region of IL-32 gene (E1 and E2). The data shown are the mean ± SEM.
Results are compiled from at least two experiments. n = 6. *p < 0.05 (RPMI versus b-glucan; by Wilcoxon test).
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Because IL-32 and IL-1b seem to play a pivotal role in the con-
trol of the infection caused by L. braziliensis in b-glucan-trained
macrophages, we evaluated whether these two cytokines as
well as macrophages-like cells were present in the lesion of
IL-32gTG mice. The predominant cells in the lesions were
macrophage-like (F4/80+) cells in both b-glucan-trained or
PBS-treated IL-32gTG mice after 3 weeks and 8 weeks of infec-
tion. Furthermore, we observed that IL-32 protein wasmainly ex-
pressed in b-glucan-trainedmice. Of note, the high expression of
IL-1b at week 3 after infection in b-glucan-trained mice
compared with the PBS group provide an extra evidence sup-
porting the concept that IL-32 and IL-1b are closely associated
with the b-glucan-induced trained immunity (Figure S4).
Figure 3. IL-1b and IL-32g Expression
Mediate b-Glucan Training
(A and B) Monocytes from individuals carrying the
CC and TT genotypes of IL32 rs4786370 SNP were
trained with RPMI or b-glucan for 24 h. Secreted (A)
and intracellular (B) IL-1b protein were measured.
(C and D) IL-32g mRNA expression (C) and intra-
cellular IL-32 protein (D) were measured in mono-
cytes after 24 h stimulation with rhIL-1b. Monocytes
were trained with RPMI or b-glucan for 24 h.
(E–I) Genetic variations in IL-1b (rs16944) (E and F),
IL-1a (rs17561) (G andH), and IL-1RAP (rs34590034)
(I) were assessed in DNA samples from healthy
volunteers from the 200FG cohort. Following LPS
restimulation on day 6, TNF-a and IL-6 production in
b-glucan-trained macrophages were assessed. The
data shown are fold increased normalized to RPMI.
Mean ± SEM; *p < 0.05 (Mann-Whitney U test).
Monocytes were trained with b-glucan ± rhIL-1Ra
for 24 h. On day 6 after b-glucan exposure, macro-
phages were infected with stationary-phase
L. braziliensis promastigotes.
(J) IL-32g mRNA expression.
(K) Infection index after 24 h of infection. The data
shown are the mean ± SEM. Results are compiled
from at least two experiments. n = 6. *p < 0.05 (RPMI
versus b-glucan; by Wilcoxon test).
Intracellular IL-32 Expression
Determines the Gene Transcription
Profile in Bone Marrow-Derived
HSPC and GMP Cells 90 Days after
BCG Vaccination of Human
Volunteers
BCG vaccination has been shown to
induce effects similar to that of b-glucan
at the level of the hematopoietic stem cells
within the bone marrow resulting in an
enhanced training ability (Kaufmann et al.,
2018; Mitroulis et al., 2018). Because
b-glucan is not yet ready to be used as a
therapeutic option to treat human diseases
(Leentjens et al., 2014), to gain further
insight into the mechanism by which IL32
rs4786370 SNP enhances the induction of
trained innate immunity, we evaluate the
gene expression in bone marrow hematopoietic stem and pro-
genitor cells (HSPC, consisting of hematopoietic stem cells
and multi-potent progenitors) and granulocyte macrophage pro-
genitors (GMP) of healthy volunteers before BCG vaccination on
day 0 (D0) and on day 90 (D90) post BCG vaccination (Figure 7A).
We focused our analyses on genes differently expressed specif-
ically between rs4786370CT_TT andCCBMcells. At day 0, prior
to BCG vaccination, IL32 expression was similar in the individ-
uals carrying the IL32 rs4786370 CT_TT and CC genotypes in
both GMP and HSPC BM cells (Figure 7B). We next analyzed
IL32 expression in GMP cells after BCG vaccination. Of note,
mean IL32 expression in GMP cells was already modulated at
day 0 after BCG exposure in individuals carrying the IL32
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Figure 4. b-Glucan-Induced Trained Immunity Acts in the Bone Marrow of IL-32g Transgenic Mice
Humanized IL-32g transgenic (IL-32gTG) mice were injected with b-glucan or PBS, and bone marrow analyses were performed after 7 days.
(A–D) On day 7, the number of cells in the bone marrow (femur) (A) and mki67 (B), csfr2b (C), and rag2 (D) mRNA expression were measured.
(E–I) IL-32g (E), IL-1b (F), hif-1a (G), pfkp3 (H), and hk3 (I) mRNA expression after ex vivo 24 h stimulation with LPS or lysates of L. braziliensis (L. braz). The data
shown are mean ± SEM of representative group of experiments performed with 5 mice per group. *p < 0.05 (PBS versus b-glucan; by Student’s t test).
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rs4786370 CC genotype and remained unaltered after 3 months
of vaccination (Figure 7B). However, after BCG vaccination, IL32
expression in HSPC cells was modulated within the different
time points. Interestingly, 3 months (M3) after exposure to
BCG, IL32 expression was higher in the individuals carrying the
IL32 rs4786370 CC genotype when compared with individuals
carrying IL32 rs4786370 CT_TT (Figure 7B).
We next investigated genes that were differentially ex-
pressed in GMP and HSPC BM cells of individuals carrying the
IL32 rs4786370 genotypes post BCG vaccination. When we
looked at the genes expressed in the GMP BM cells, we found
some genes that were specifically upregulated in the IL32
rs4786370 CC individuals 3 months (D90) post vaccination.
Among these were genes related to cell metabolism such as
Figure 5. b-Glucan Training in IL-32gTGMice
Improves the Control of Infection Caused by
L. braziliensis
(A) WT and IL-32gTG mice were injected with
b-glucan or PBS and subcutaneously infected in
footpad with stationary-phase L. braziliensis pro-
mastigotes after 7 days.
(B) Lesion size (in millimeters; for each mouse, the
size of the infected footpad was subtracted by size
of the uninfected control footpad) was monitored
weekly.
(C) Parasite load of tissuemeasured after 8 weeks of
infection.
(D and E) TNF-a (D) and IL-32 (E) production per mg
of tissue measured in the footpad macerated after
8 weeks of infection. The data shown are mean ±
SEM of representative group of experiments per-
formedwith 6mice per group. *p < 0.05 (PBS versus
b-glucan; by Student’s t test).
oxidative stress-associated Src activator
(FAM120A), which is a critical component
of the oxidative stress-induced survival
signaling (Tanaka et al., 2009), C2 cal-
cium-dependent domain containing 4
(C2CD5), which encodes one of the pro-
teins required for insulin-stimulated
glucose transport, and glucose transporter
SLC2A4/GLUT4 translocation to the
plasma membraned of cells (Yu et al.,
2013), as well as long chain fatty acid
transport protein 1 (SLC27A1), which plays
a pivotal role mediating the ATP-depen-
dent import of long-chain fatty acids into
the cell by mediating their translocation at
the plasma membrane (Ochiai et al.,
2019) (Figure 7C). In addition, the results
also showed a clear pattern of genes that
were only expressed in HSPC BM cells of
IL32 rs4786370 CC individuals at D90
post vaccination (Figure 7D). These ana-
lyses revealed upregulation of genes
associated with inflammatory immune
response, DNA-binding transcription fac-
tor activity such as nuclear factor kB (NF-kB) subunit p65
(RELA) (Kunkl et al., 2019), bromodomain-containing 7 (BRD7),
and hepatocyte nuclear factor 1-beta (HNF1b) (Wu et al., 2017;
Park et al., 2014), a gene associated with the activation of inflam-
masome machinery such as NLR family pyrin domain containing
1 (NLRP1) (Finger et al., 2012), as well as transmembrane
signaling receptor activity such as tumor necrosis factor recep-
tor superfamily member 8 (TNFRSF8) (Luo et al., 2018)
(Figure 7D).
These data strengthen the finding that IL-32 is a crucial
component in the regulation of events occurring at the level of
the hematopoietic stem progenitor cells, which confer the devel-
opment of the trained immunity phenotype leading to protection
against L. braziliensis infections.
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DISCUSSION
Several recent studies describe the ability of human innate im-
mune cells to build a de facto immunological memory against
pathogens and microbial products (Kleinnijenhuis et al., 2012;
Netea et al., 2016). The fungal cell wall component b-glucan is
a prototypical inducer of trained immunity in vitro and in vivo,
stimulating a long-term pro-inflammatory macrophage pheno-
type capable of mounting an augmented response to infection.
Importantly, the trained immunity response is heightened non-
specifically, triggered by infections unrelated to the initial training
stimulus (Ifrim et al., 2014). In this series of experiments, we
demonstrated that induction of trained immunity by b-glucan
modulates IL-32-mediated control of Leishmania infection via
IL-1 signaling and epigenetic changes. These findings improve
our understanding of the mechanism of trained immunity
induced by b-glucan and simultaneously point toward different
avenues for pharmacotherapy for improved treatment of
leishmaniasis.
Specifically, we have shown that induction of trained immunity
by b-glucan increases the efficiency of phagocytosis and killing
of L. braziliensis, in parallel with increased cytokine production,
Figure 6. Histopathological Analyses of
Paw’s Lesions of IL-32gTG Mice Previously
Treated with b-Glucan and Infected with
L. braziliensis
WT and IL-32gTGmice were injected with b-glucan
or PBS and subcutaneously infected in footpadwith
stationary-phase L. braziliensis promastigotes after
7 days.
(A–C) Representative photomicrographs of histo-
pathological profile of footpad lesions: (A) unin-
fected paw of IL-32gTG and WT mice, (B) PBS
group after 3 weeks of infection, and (C) b-glucan
group after 3 weeks of infection.
(D) Inflammation scores after 3 weeks of infection.
(E–J) PBS group after 8 weeks of infection (E andH).
b-glucan group after 8 weeks of infection (F and I).
Inflammation scores after 8 weeks of infection
(G and J). Scores were based on cell density as 0:
no inflammation; 1: mild; 2: moderate; 3: intense;
scale bar is 100 mm. The data shown are mean ±
SEM of representative group of experiments per-
formed with 4 mice per group. *p < 0.05 (PBS
versus b-glucan; by Student’s t test).
specifically IL-6 and IL-10. It has previ-
ously been demonstrated that dectin-1
and the complement receptor 3 (CR3) re-
ceptors are required to induce training of
monocytes with b-glucan (Quintin et al.,
2012). These findings could at least partly
explain the increased capacity for phago-
cytosis by b-glucan-trained cells, because
both dectin-1 and CR3 are reportedly
involved in Leishmania uptake by macro-
phages (Martı´nez-Lo´pez et al., 2018).
Considering macrophage microbicidal ac-
tivity, we assessed induction of ROS and
NO production (Novais et al., 2009). However, b-glucan training
did not alter any of these mediators. These results are in line with
previous findings (Bekkering et al., 2016) that reported no differ-
ences in ROS and NO induction in b-glucan-trained cells
compared with naive cells. On the other hand, b-glucan-trained
cells produced higher levels of antimicrobial peptides such as
cathelicidin and b-defensin 2, which have been previously asso-
ciated with improved killing of Leishmania spp. in human macro-
phages (Dos Santos et al., 2017b; Kulkarni et al., 2011).
Because IL-32 has been described as a crucial mediator to
control Leishmania infections through transcriptional induction
of antimicrobial peptides, we explored the role of IL-32 in
b-glucan-induced trained immunity. Significant induction of
IL-32 expression suggested that b-glucan training influenced
gene regulatory mechanisms. Indeed, histone methylation
changes, namely H3K4me3 enrichment, are induced by
b-glucan at the promoters of numerous pro-inflammatory genes
such as TNF-a and IL-6 (Quintin et al., 2012). In contrast, we
observed that the IL-32 gene promotor region became depleted
of H3K4me3 upon training with b-glucan. Importantly, we identi-
fied a training-specific H3K4me1 enhancer signature located
downstream of the IL-32 gene transcription start site. Enhancers
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are distal cis-regulatory elements essential to controlling gene
expression programs (Schaffner, 2015) and are thought to play
crucial roles in the establishment of distinct macrophage pheno-
types (Denisenko et al., 2017). Recently, it has been demon-
strated that this particular enhancer element modulates the
expression of the different isoforms of IL-32 to regulate inflam-
matory states of immune cells during HIV-1 infection (Palstra
et al., 2018). Thus, from our limited profiling of the chromatin
landscape surrounding IL-32 transcriptional regulation, it might
be tempting to speculate that activating histone modifications
at distal regulatory elements may be more important for IL-32
expression than those at proximal elements.
However, the importance of the IL-32 promoter cannot be
overlooked, as shown by the fact that the expression of IL-32
is also altered by promoter SNPs (Westra et al., 2013). The CC
genotype of IL-32 rs4786370 SNP was previously associated
with enhanced IL-32 protein production. We therefore examined
the effect of this particular SNP in b-glucan-induced trained im-
munity. In accordance with previous reports (Plantinga et al.,
2013), we found that TNF-a, IL-6, and lactate production were
higher in individuals carrying the CC genotype compared with
those carrying the TT genotype in b-glucan-trained cells. More-
over, by assessing the influence of the IL32 promoter SNP on
the infection index, we demonstrated that besides its important
role for cytokine production in LPS restimulated macrophages,
IL-32 levels were negatively associated with infection index rates
in individuals carrying the CC genotype. What is the direct role of
IL-32 in the induction of trained innate immunity is not known at
this moment. However, because IL-32 is mainly expressed intra-
cellularly in b-glucan-trainedmacrophages, it might be that IL-32
is acting like other intracellular cytokines such as IL-1a, IL-33,
and IL-37 (Dinarello, 2011; Moorlag et al., 2018). In addition, a
recent study has pointed that IL-32 also can function as a tran-
scription factor, because it appears to bind to DNA impairing
the transcription and viral replication during infections (Kim
et al., 2018). Further work is required in order to understand
the mechanistic significance of IL-32 in b-glucan-trained macro-
phages, including epigenetic mechanisms not explored in the
current study such as DNA methylation (Meyer et al., 2015), as
well as transcription factor binding.
It has previously been shown that IL-32 is able to induce
several proinflammatory cytokines, such as IL-1b, IL-8, and
TNF-a. Furthermore, IL-1 and TNF-a can induce IL-32 (Heinhuis
et al., 2011; Kim et al., 2005; Netea et al., 2005). Recent reports
pointed toward a role for IL-1 in the induction of b-glucan-
induced trained immunity in vivo (Mitroulis et al., 2018). In addi-
tion, Arts et al. (2018) demonstrated that IL-1b itself can induce
trained immunity. In the present study, we were able demon-
strate that IL-32 and IL-1 regulate the expression of each other
in the context of trained innate immunity. Here, we showed
that the IL32 rs4786370 is associated with IL-1b production dur-
ing the early stages of training with b-glucan. Additionally, IL-1b
Figure 7. Human Bone Marrow Analyses in BCG-Vaccinated Individuals Stratified Based on IL32 rs4786370 Genotypes
(A) Study design including BCG-vaccinated individuals (n = 15; IL32 rs4786370 CC genotype = 2) and placebo-treated controls (n = 5; IL32 rs4786370 CC
genotype = 2). Bone marrow aspirations were analyzed before day 0 (D0) and day 90 (D90) after vaccination.
(B) IL32 expression in granulocyte macrophages progenitors (GMPs) and in hematopoietic stem and progenitor cells (HSPCs) from individuals stratified for the
different IL32 rs4786370 genotypes (CT/TT and CC) at D0 and D90 after BCG-vaccination.
(C and D) Heatmap representation of differentially expressed genes in IL32 rs4786370CT/TT versus CCGMPs (C) and HSPCs (D) (BCG, D0 versus D90). Samples
are separated in columns based on time point and IL32 rs4786370 genotypes. Names of genes associated with the different genotypes are shown.
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protein was higher at the lesion of b-glucan-treated IL-32gTG
mice after 3 weeks of infection. On the other hand, IL-1b itself
also upregulates the production of IL-32. Moreover, we
confirmed the role of IL-1 in the induction of trained immunity
by using functional genomic analysis and IL-1 receptor
blockade. Inhibition of IL-1 signaling downregulated IL-32
expression, which in turn decreased the killing of Leishmania
parasites. Of note, we cannot exclude that the presence of
IL-1b as a detrimental consequence, resulting in of chronic
inflammation. IL-1b has been previously associated with CD8+
cell-mediated toxicity in lesions of patients with cutaneous leish-
maniasis (Novais et al., 2017). Furthermore, it cannot be dis-
counted that the IL-1-dependent TNF-a and IL-6 induction after
b-glucan training might also play a role in the induction of IL-32,
therefore contributing to the killing of Leishmania parasites. As
demonstrated previously (Heinhuis et al., 2011), IL-32 and
TNF-a are part of an inflammatory loop. Moreover, TNF-a has
also been associated with IL-32 in ML caused by L. braziliensis
(Galdino et al., 2014).
As the results indicated that IL-32 is important for b-glucan-
induced trained immunity in human macrophages in vitro, we
evaluated the effect of b-glucan-induced trained immunity in hu-
man IL-32gTG mice infected with L. braziliensis. In these mice,
b-glucan training induced proliferation of bone marrow cells. In
addition, in agreement with the results previously shown by Mi-
troulis et al. (2018) using WT mice, we suggested that myeloid
cells might be playing the major role in control the infection
caused by L. braziliensis in IL32gTG mice. Furthermore, an
enhanced IL-32 and IL-1b expression, as well as upregulation
of genes involved in glycolysis, upon exposure to LPS or lysates
of L. braziliensis was reported (Figure 4). Once again, these find-
ings are in line with those from a previous study, in which
changes in progenitor cells of WT mice such as increased pro-
duction of IL-1b and enhanced glycolysis accompany the induc-
tion of trained innate immunity (Cheng et al., 2014;Mitroulis et al.,
2018).Moreover, it was also shown that BCG influences hemato-
poietic stem cells to generate epigenetically modified macro-
phages that provide significantly better protection against
M. tuberculosis infection (Kaufmann et al., 2018). Of great inter-
est, as a proof of concept, wewere able to demonstrate that after
BCG vaccination of healthy individuals, IL-32 has effects at the
level of BMprogenitor cells bymodulating signature genes asso-
ciated with inflammation, DNA binding transcript factors, and
metabolism, including pathways known to be important for the
long-term induction of trained immunity (Mulder et al., 2019). Ne-
tea et al. (2008) previously described that IL-32 contributes to
differentiating monocytes into macrophage-like cells, resem-
bling the phenotypical changes seen after b-glucan exposure.
Additionally, IL-32 modulates the expression of ABCA1 and
ABCG1 resulting in changes in lipid concentrations in primary
human hepatocytes (Damen et al., 2018). Although we have
not evaluated deviations in lipid metabolism, it is likely that
IL-32 plays a role in metabolic changes necessary for cell adap-
tation during the induction phase of trained immunity with
b-glucan.
Successful treatment of leishmaniasis is limited in the most
parts of the world due to the toxicity and costs of effective medi-
cation. Moreover, a functional vaccine against the Leishmania
spp. infections in human is still under development. However,
a safe and effective leishmaniasis vaccine might be based on
whole irradiated live parasites or Leishmania fractions, such as
Leishmania-derived recombinant poly-protein (LEISH-F), as
well as DNA vaccines (Rezvan and Moafi, 2015). It would be of
considerable interest to combine vaccine components that
target the enhancement of Th1 responses against Leishmania
with strategies such as induction of trained immunity, especially
to improve memory development for long-term protection. In
therapy, especially in the cases where an acquired immune
response is not present or is not effective such as in DCL, induc-
tion of trained immunity may be crucial to contain the parasite
proliferation and dissemination. As a proof of concept, treatment
of patients with DCL with BCG provides control of parasites and
long periods without relapses, improving the quality of the pa-
tient life (Convit et al., 2004; Pereira et al., 2009). Thus, in addition
to BCG training, b-glucan training represents another approach
to control leishmaniasis in these patients. Moreover, b-glucan
treatment may be an alternative when BCG, after several injec-
tions, could no longer be used due to the induction of strong ac-
quired immune response in the local site of injection (Pereira
et al., 2009).
In conclusion, we have shown that b-glucan improves host de-
fense against L. braziliensis via the induction of trained immunity,
highlighting IL-1 signaling and IL-32g as important mediators for
the eradication of Leishmania parasites. This study represents a
definitive characterization of the role of IL-32g in the trained
phenotype induced by b-glucan. Our results begin to unravel
the molecular mechanisms governing trained immunity and
Leishmania infection control. Finally, the demonstration that
b-glucan is able to improve the control of Leishmania infection
using several mechanisms opens the gates for treatment strate-
gies using trained immunity.
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bglucan (b1,3-(D)-glucan Professor David Williams,
College of Medicine,
Johnson City, USA
N/A
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Lipopolysaccharide Sigma-Aldrich Cat#L2880From E. coli serotype 055:B5,
Recombinant human Interleukin-1Ra Sobi Kineret Anakinra
Recombinant human Interleukin-1b R&D systems Cat#201-LB-005
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Zymosan Sigma-Aldrich Cat#Z4250
Griess reagent Sigma-Aldrich Cat#G4410
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miRNeasy Micro Kit QIAGEN Cat#217084
QIAseq FX Single Cell RNA Library Kit QIAGEN Cat#180733
KAPA Library Quantification Kits Kapa Biosystems Cat#07-KK4852-01
Deposited Data
Raw and analyzed data This paper GEO: GSE124220
Raw and analyzed data This paper GEO: GSE132155
Blood eQTL browser N/A https://genenetwork.nl/bloodeqtlbrowser/
Experimental Models: Organisms/Strains
200FG cohort (Human Functional Genomics project) N/A http://www.humanfunctionalgenomics.org
Transgenic mice for human IL-32 (IL-32TGg) Choi et al., 2010 N/A
Leishmania Viannia braziliensis Oliveira et al., 2010 MHOM/BR/2003/IMG
BCG vaccine (Bulgaria strain) Intervax N/A
Oligonucleotides
See Table S1 This paper N/A
Software and Algorithms
GraphPad Prism Graphpad Software https://www.graphpad.com
VisionTEK Sakura https://www.visiontek.com
FlowJo Tree Star RRID:SCR_008520
R statistical programming N/A RRID:SCR_001905
DESeq2 N/A RRID:SCR_015687
Bioconductor N/A RRID:SCR_006442
clusterProfiler N/A RRID:SCR_016884
pheatmap N/A RRID:SCR_016418
ggplot2 N/A RRID:SCR_014601
fGSEA Bioconductor https://bioconductor.org/packages/fgsea
tximport N/A RRID:SCR_016752
flowCore N/A RRID:SCR_002205
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Leo Joos-
ten (leo.joosten@radboudumc.nl). This study did not generate unique reagents. There are no restrictions to the availability of reagents
used in the current study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Experiments were conducted according to the principles expressed in the Declaration of Helsinki. All blood donors (Sanquin Blood
Bank, Nijmegen, the Netherlands) gave written informed consent before donating the blood. The volunteers (n = 120) from the 200FG
cohort (http://www.humanfunctionalgenomics.org) were between 23 and 73 years old and consisted of 77% males and 23% fe-
males. A randomized controlled trial (Trial NL6003 [NTR6501] https://www.trialregister.nl/trial/6003) was conducted at the Radboud
University Medical Center (Nijmegen, the Netherlands) from January 2017 to July 2017. Prior to inclusion, volunteers were medically
screened and provided written informed consent. The trial was approved by the Arnhem-Nijmegen Ethical Committee (approval
number NL55825.091.15). The healthy volunteers (n = 20) were between 18 and 50 years old and consisted of 65% males and
35% females.
Animals
Transgenic mice for human IL-32 were generated (Choi et al., 2010) and kindly donated by Professor Charles Dinarello (University of
Colorado, Denver, USA). Wild-type C57BL6J and IL-32gTG mice (females) between 8-10 weeks old were used in the experiments.
Mice weremaintained in animal facility of Instituto de Patologia Tropical e Sau´de Pu´blica of Federal University of Goia´s, Goia´s, Brazil.
The study was approved by Ethics Committee of Radboud University Nijmegen, the Netherlands (approval number 42561.091.12)
and also by Ethics Committee for animal research of Universidade Federal de Goia´s (CEUA/PRPI/UFG, protocol 042/16). All animal
experiments were in accordance with the guidelines of legislation of ethics of the Brazilian Society of Science in Laboratory Animals
(SBCAL) and National Council of Control of Animal Experimentation (CONCEA).
Leishmania braziliensis parasites
L. braziliensis (MHOM/BR/2003/IMG) strain was obtained as previously described (Oliveira et al., 2010). Promastigote forms were
cultured in Grace’s insect medium (GIBCO, Life Technologies, USA) supplemented with 20% of heat-inactivated fetal bovine serum
(FBS, GIBCO, Life Technologies, USA), 100 U/mL of penicillin/streptomycin (Sigma-Aldrich) at 26C. Stationary-phase parasites
were obtained on 6th day of growth and washed three times with phosphate-buffered saline (PBS; 1000xg, 10 min 10C). After,
they were suspended in PBS and quantified by using hemocytometer after fixation with PBS/0.4% formaldehyde. Live parasites
were used in macrophage infection experiments. In addition, parasite lysates were obtained by 5 freeze-thaw cycles of promasti-
gotes in the presence of protease inhibitors (Protease inhibitor cocktail, Sigma-Aldrich), in liquid nitrogen followed by water bath
at 37C. Protein quantification was performed by using Pierce BCA protein assay kit (ThermoFisher Scientific, USA).
METHOD DETAILS
Peripheral Blood Mononuclear Cells (PBMC) and monocyte isolation
PBMC isolation was performed by dilution of blood in pyrogen-free PBS and differential density centrifugation over Ficoll-Paque (GE
healthcare, UK) as previously described (Dos Santos et al., 2017a). Percoll isolation of monocytes was performed as previously
described (Repnik et al., 2003). Briefly, 150-200 3 106 PBMCs were layered on a hyper-osmotic Percoll solution (48.5% Percoll,
41.5% sterile water, 0.16 M NaCl) and centrifuged for 15 minutes at 580 g (4C). The interphase layer was collected and cells
were washed with cold PBS. Cells were resuspended in RPMI 1640 culture medium (Roswell Park Memorial Institute medium; Invi-
trogen, USA) supplemented with 50 mg/mL gentamicin, 2 mM glutamax (GIBCO, Life Technologies, USA), and 1 mM pyruvate
(GIBCO) and quantified. Cells (10 3 106 cells/10 mL) were allowed to adhere on Petri dishes plates (Corning, NY, USA) for 1 h at
37C. Non-adherent cells were washed out with warm PBS and monocytes were recovered from the plates by adding 6 mL of ver-
sene (GIBCO, Life Technologies, USA) for 30 min, at 37C.
Monocyte training, treatments and macrophage infection
Trained immunity was induced in adherent monocytes as described previously (Bekkering et al., 2016). Cells were incubated either
with culture medium containing 10% pooled human serum, referred as complete medium, as a negative control or 5 mg/mL of
b-glucan (b-1,3-(D)-glucan was kindly provided by Professor David Williams, College of Medicine, Johnson City, USA). After 24 h
(37C), cells were washed once with 10 mL of warm PBS and incubated for 5 days with one change of complete medium. On day
6, cells were harvested and counted. 1 3 106 cells were stored in 200 mL of TRIzol (Invitrogen) at 80C until RNA extraction.
13 106 cells were stored in 100 mL of 0.5% Triton X-100 (Sigma-Aldrich) for intracellular IL-32 measurement. 5 3 105 cells in a final
volume of 500 mL of complete medium were added into 24-well plates on 12 mm coverslips (Corning, NY, USA), adhered for 1 h at
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37C and infected with stationary-phase promastigotes of L. braziliensis (2.5 3 106/well; MOI 5:1). Percentage of infected macro-
phages, number of parasites per infected cells and infection index were measured after 2 h, 4 h and 24 h of infection. 1 3 105 cells
in a final volume of 100 mL of culture medium were added into flat-bottom 96-well plates (Corning, NY, USA), adhered for 1 h at 37C
and restimulated with 10 ng/mL of lipopolysaccharide (LPS) from E. coli serotype O55:B5, (Sigma-Aldrich), further purified as
described (Battisti and Minnick, 2008) and stationary-phase L. braziliensis promastigotes (5 3 105/well; MOI 5:1). Supernatants
were collected after 2 h, 4 h and 24 h and stored at 20C. In some experiments cells were pre-incubated (before b-glucan) for
1 h with 10 mg/mL of recombinant interleukin-1 receptor antagonist (IL-1Ra; Synergen, USA) to evaluate the IL-1 effects during
the priming with b-glucan. After 24 h stimuli and inhibitors were washed away and the assay continued as described above. Addi-
tionally, 13 106 monocytes were stimulated with 10 ng/mL of rhIL-1b (R&D systems) for 24 h at 37C. After 24 h cells were stored in
200 mL of TRIzol until RNA extraction.
Evaluation of Macrophage infection
Infection index were performed as previously described (Dos Santos et al., 2017b). Coverslips were collected, cells were fixed and
stained with Giemsa (MerckMillipore) and analyzed under a light microscope (1000x) to determine the infection index. Three hundred
cells were analyzed and the percentage of infected cells and the mean number of intracellular parasites per infected cell (at least 50)
were determined. Infection index = percentage of infected cells 3 mean number of parasites per infected cell.
Reactive oxygen species and nitric oxide measurements
For measurement of ROS production, a luminol-enhanced luminescence assay was used. After detachment and counting of trained
monocytes, a total of 13 105 cells were added perwell of a white-96well assay plate (Corning) in a volume of 200 mL. Cells were either
stimulated with zymosan from Saccharomyces cerevisiae (1 mg/mL; Sigma-Aldrich) or with stationary-phase promastigotes of
L. braziliensis (5 3 105/well; MOI: 5:1). Luminol (145 mg/mL) was added and chemiluminescence was measured for 1 h. For NO,
1 3 106 cells were trained and nitrite was determined in supernatants on day 6 by using Griess reagent (Sigma-Aldrich). Prior to
the assay, the human serum was precipitated from the supernatants using perchloric acid (PCA 13.5% - Fluka) and neutralized
with 4 N NaOH.
Chromatin immunoprecipitation (ChIP)
Monocytes were isolated and trained with b-glucan as described above. On day 6, cells were harvested and fixed in 1% methanol-
free formaldehyde. Fixed cell preparations were sonicated using Diagenode Bioruptor Pico sonicator using 5 cycles of 30 s on/30 s
off and CHIP was performed using antibodies against H3K4me3, H3K9me3, H3K4me1 (Diagenode, Seraing, Belgium). A MinElute
PCR purification Kit (QIAGEN) was used for DNA isolation. Afterward, qPCR analysis was performed using SYBR Green method
and samples were analyzed by a comparative Ct method. Primers are listed in Table S1.
Genetic Analysis in the 200FG cohort
Genetic variation was assessed in the genes of IL-32 and IL-1b in healthy individuals of Western European descent from the 200FG
cohort (Li et al., 2016). Monocytes were isolated and trained with b-glucan as described above. After 24 h, supernatants were
collected and IL-6 and TNFa production was measured by ELISA. In some experiments, the individuals were selected according
with their genotypes for the IL32 rs4786370 SNP. PBMCs isolation and training protocol were performed as described above. After
24 hours of training, IL-1b production wasmeasured by ELISA. On day 6, trained macrophages were infected with L. braziliensis pro-
mastigotes (5 3 105/well; MOI 5:1) and the infection index was measured as described above.
In vivo b- glucan training experiments
Wild-type C57BL6 and IL-32gTG mice were injected intraperitoneally (i.p.) with 1 mg (Cheng et al., 2014) of b-D-glucan from barley
(Sigma- Aldrich) in 200 mL of PBS; as control, i.p. injection of PBS alone was performed; After 7 days, animals were infected with
stationary-phase of L. braziliensis promastigotes (1 3 105/50 mL of PBS per mice) subcutaneously into the left posterior footpad.
Lesion size (mm) was measured weekly using a digital caliper and expressed as the difference between the thickness of the infected
and uninfected footpad. After 3 weeks and 8weeks of infection, micewere euthanized and their footpads were removed for analyses.
Infected paw was weighed and macerated in PBS. Parasite load was then analyzed by the limiting dilution assay. The results were
expressed as the negative logarithm of the parasite titer per footpad (de Souza-Neto et al., 2004). To measure cytokines concentra-
tions in the lesion, tissue samples were prepared as previously described (Gomes et al., 2018).
Ex vivo bone marrow stimulation after in vivo b- glucan training
Mice were injected with b-glucan as described above. On day 7, bone marrow from both femurs and tibiae was harvested in culture
RPMI 1640 medium supplemented with 10% heat-inactivated FBS. Cells were counted and the concentration was adjusted for 53
106 cells/mL. 13 106 cells were stored in 200 mL of TRIzol at 80C for RNA extraction. Subsequently, 53 105 cells in 100 mL were
seeded in flat-bottom 96-well plates, stimulated with 100 mL of LPS (10 ng/mL) or L. braziliensis lysates (50 mg/mL) and incubated for
24 h, at 37C. Supernatants were collected for cytokine measurements and cell monolayers were stored in 200 mL of TRIzol at80C
for RNA extraction.
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Cytokine and lactate measurements
Cytokine production was determined in supernatants using commercial ELISA kits (R&D Systems) for human TNFa, IL-6, IL-10, IL-32
and IL-1b. For mouse, bonemarrow culture supernatants, and supernatants from footpad homogenates were used tomeasure TNFa
and IL-32 (kits from R&D Systems), according the instructions of the manufacturer. Lactate concentration was measured in super-
natants of human macrophages using Lactate Fluorometric Assay kit (Biovision, CA, USA).
RNA isolation and qPCR
RNA was isolated using Trizol (Chomczynski and Sacchi, 1987). RNA was precipitated with isopropanol and washed with 75%
ethanol followed by reconstitution in RNase-free water. Subsequently, RNA was reversely transcribed into cDNA by using iScript
(Bio-Rad, Hercules, CA, USA). Diluted cDNA was used for qPCR that was done by using the StepOnePlus sequence detection sys-
tems (Applied Biosystems, Foster City, CA, USA) with SYBR Green Mastermix (Applied Biosystems). Genes evaluated in humans
were: IL-32, cathelicidin, b-defensin 2, and in mice were: mki67, csf2rb, rag2, IL-1b, hif-1a, pfkp3, hk3. The mRNA analysis was
done with the 2^ -dCt x 1000 method and normalized against the housekeeping gene b2M for humans and 18 s for mouse. Primer
sequences are listed in Table S1.
Histopathological analysis
Paraformaldehyde fixed-footpad lesions of L. braziliensis-infected mice (3 or 8 weeks of infection) were embedded in paraffin to be
processed for histological analysis. Sections of 5 mm in thickness were stained with Hematoxylin and Eosin (H&E). Histopathological
changes between PBS and b-glucan group mouse lesions were analyzed using a digital microscope VisionTek (Sakura, Japan),
determining the cell density in the inflammatory infiltrate. One hundred microscope fields per section were analyzed. Semiquantita-
tive score was performed according with the number of cells per field and classified in 0: none; 1: mild; 2: moderate; 3: intense.
Immunohistochemical (IHC) analysis for F4/80
Paraffin-embedded sections of footpad lesions were stained by the DAB (303 diaminobenzidine) method using: rat primary mono-
clonal anti-mouse F4/80 antibody (AbD Serotec, UK) followed by secondary biotinylated rabbit anti-rat antibody (Vector Labora-
tories, USA); goat primary polyclonal antibody anti-human IL-32 (R&D Systems, MN, USA) followed by secondary biotinylated horse
anti-goat antibody (Vector Laboratories, USA); rabbit primary polyclonal antibody anti-mouse IL-1b (ThermoFisher Scientific, USA)
followed by secondary biotinylated goat anti-rabbit antibody (Vector Laboratories, USA). Tissues were counterstained with Meyer’s
hematoxylin. Macrophages were visualized with 3,3-diaminobenzidene precipitation (DAB, Vector Laboratory). All sections were
analyzed using VisionTek (Sakura, Japan) Live Digital microscope.
Human Bacille Calmette-Gue´rin vaccination
Twenty healthy BCG-naive volunteers were included and randomly assigned to two groups: 15 subjects (10 males and 5 females)
received standard dose (0.1mL of the reconstituted vaccine) of intradermal BCG vaccination (BCGBulgaria, Intervax), and 5 (3males
and 2 females) received 0.1 mL of vaccine diluent as a placebo control. At baseline (D0) and after three months (D90), bone marrow
was extracted by aspiration from the iliac crest by an experienced physician assistant after local anesthetics with lidocaine. 30 mL of
bonemarrow was aspirated in total and collected into two 20mL syringes, prefilled with 5 mL (150 IE/ml) sodium heparin per syringe.
EDTA blood was collected and stored at 80C until further processing for IL32 genotyping.
Isolation of genomic DNA and genetic assessment of IL32 rs4786370 SNP
DNAwas isolated from EDTA venous blood using the DNeasy Blood & Tissue Kit (QIAGEN, Venlo, the Netherlands), according to the
manufacture’s protocol. Genotyping of individuals was performed by TaqMan SNP assay (IL32 rs4786370, Applied Biosystems),
according to the manufacture’s protocol on the StepOnePlus qPCR system (Applied Biosystems). Quality control was performed by
the incorporation of positive and negative controls and duplication of random samples.
Flow cytometric analysis and sorting
Bone marrow aspirates were collected and enriched for the mononuclear cell fraction (BMMNC) on D0 and D90. Cells were washed
in FACS-buffer (0.5% BSA, 2 mM EDTA, PBS), resuspended in blocking buffer (1% rat serum (R9759-10ML; Sigma-Aldrich, USA),
1% mouse serum (M5905-5ML; Sigma-Aldrich, USA), 5% human serum (H4522-100ML; Sigma-Aldrich, USA) in FACS-buffer) and
incubated with the respective antibody cocktails for two hours on ice in the dark (Table S2). Cells were washed, resuspended in
FACS-buffer and incubated with the live/dead marker DRAQ7 (1:1000, BioLegend, USA) for 5 min at room temperature. Samples
were acquired using BD FACS ARIAIII (BD Biosciences) and the FACS Diva software (BD Biosciences, USA). For RNA isolation
from hematopoietic stem and progenitor cells HSPCs (identified as alive Lin-CD34+CD38-CD45RA-CD90+/) and GMPs (identified
as alive Lin-CD34+CD38+CD45RA+CD10-), cells were first sorted into cooled 1.5 mL reaction tubes containing FACS-buffer. Cells
were pelleted at 2200 rpm for 7 min at 4C and vigorously resuspended in 500 ml Qiazol. Tubes were stored at 80C until further
processing.
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Generation and sequencing of cDNA libraries for transcriptome analysis
Total RNA was isolated using the miRNeasy Micro Kit (QIAGEN GmbH, Germany) according to the manufacturer’s guidelines. RNA
concentration and quality were assed using the Tapestation 2200 system and high sensitivity reagents (Agilent Technologies, USA).
Sequencing libraries of FACS-enriched populations were prepared following the QIAseq FX Single Cell RNA Library Kit protocol
(QIAGEN GmbH, Germany). For QIAseq FX Single Cell RNA Libraries, concentration of cDNA was assessed by KAPA Library Quan-
tification Kits (Kapa Biosystems, USA) before sequencing single read 75bp on a HiSeq1500 instrument using TruSeq SBS v3-HS
chemistry.
RNA-sequencing pre-processing and data analysis
For pre-processing, data were demultiplexed using bcl2fastq2 (v.2.20). Quality controls were performed by FastQC, reads aligned to
human reference transcriptome hg38 fromUCSC and transcript abundance quantified using kallisto (v0.440) with default parameters.
Further analysis was based on at least 5 million sequenced reads. Samples were imported with tximport (v1.8.0) and transcripts were
filtered to remove those not corresponding to HGNC gene symbols, read sum lower than 10 across all samples or matching anti-
sense, LINC or pseudogenes. One sample (derived from donor 9 HSPC, D0) was identified as outlier and omitted due to prominent
de-clustering of the sample in the PCA based on normalized reads of the top 5000 most variable transcripts. Core analysis of the
cleaned RNA-sequencing dataset is based on the DESeq2 package (v1.20.0) in R and potential confounding effects are taken
into account by incorporating gender and batch of library preparation into the DESeq2 object design matrix. The individuals were
stratified based on their IL32 rs4786370 genotypes and genes were called differentially expressed if reaching an adjusted p value
(padj) < 0.05 after multi-testing correction after Benjamini-Hochberg. Expression values were adjusted using variance stabilizing
transformation (vst) and heatmaps were visualized with pheatmap (v1.0.10).
QUANTIFICATION AND STATISTICAL ANALYSIS
Differences were analyzed using Student’s t test, Wilcoxon signed-rank test and Mann-Whitney U test, where applicable. For cyto-
kine production before and after b-glucan training, the data are shown as fold increases or raw cytokine compared to the RPMI con-
trol. The statistics analyses were performed on these ratios. Analyses were performed using Prism software version 6.0 (GraphPad,
San Diego, CA, USA). Significance was established as p < 0.05.
DATA AND CODE AVAILABITY
RNA sequencing data are available under GEO Accession number GEO: GSE124220 and GEO: GSE132155 for HSPC and GMP,
respectively; Scripts used to analyze these data will be shared upon request.
Additional Resources
A randomized controlled trial (Trial NL6003 [NTR6501] https://www.trialregister.nl/trial/6003) was conducted at the Radboud Univer-
sity Medical Center (Nijmegen, the Netherlands) from January 2017 to July 2017.
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